1/88
Looks like no tags are added yet.
unpleasant sensory and emotional experience associated with actual or potential tissue damage
pain
condition characterized by apprehension, increased motor activity, and autonomic arousal
state of anxiety accompanied by motor restlessness
agitation
syndrome characterized by acute cerebral dysfunction with a change or fluctuation in baseline mental status
disturbed level of consciousness and change in cognition OR development of a perceptual disturbance
delirium
what is an issue with pain management in ICU patients
may be unable to self report pain
pain related stress response
increases sympathetic nervous system activation, vasoconstriction, impaired wound healing, alter breathing patterns
gold standard of monitoring pain
patient self reporting
what to use if a patient is unable to self report pain
behavioral pain scale (BPS), critical care pain observation tool (CPOT)- uses facial expression and body movements
preferred method for preemptive analgesia in non-neuropathic pain
IV opioids
feature of opioids that must be considered
may have sedative effects
what to use to decrease opioid requirements
non-opioid analgesics (acetaminophen, neuropathic pain meds, ketamine, MAYBE NSAIDs)
frequent in critically ill patients, associated with adverse clinical outcomes and examples
agitation- ventilator dysynchrony (difficult to mechanically ventilate), physical aggression, increased motor activity
underlying causes of agitation
pain
mechanical ventilation
delirium
hypoxia
hypotension
withdrawal
non pharm treatment of agitation
patient comfort, adequate analgesia, normal sleep
required by most patients with mechanical ventilation
pharmacological sedation
the act of calming, by the administration of a sedative drug
mainstay for treatment of agitation/anxiety in ICU
sedation
state of minimal motor activity that is physically similar to sleep, artificially induced
hypnosis
reduction of emotional and physical responses to real/ perceived danger
anxiolysis
when to start pharmacological sedation
after providing adequate analgesia and treating reversible physiological causes
what to NOT use sedation for
method of restraint, coercion, discipline
what occurs with over sedation
increased time on mechanical ventilation, increased ICU stay time, obscure neurological function testing
best plan with sedation
LESS IS BEST
how to achieve light sedation
daily sedation interruption, nursing protocolized targeted sedation to facilitate titration of sedatives
subjective assessment options for sedation and when can these not be used
RASS and SAS, difficult in patients with altered level of mentation
objective assessment of sedation
bispectral index (BIS), scale of 100 (completely awake) to 0 (isoelectric EEG)
who is EEG monitoring recommended for
non-convulsive seizure activity in ICU patients and patients whom other measures are not feasible (deep sedation or neuromuscular blockade)
ideal sedative agent
rapid onset, minimal respiratory depression, no drug interactions, no tolerance, inexpensive, does not contribute to delirium
sedative drugs used in the ICU
BZDs, propofol, dexmedetomidine
MOA of BZDs
Binds to a specific site on GABA (a) receptors, enhances GABA-mediated neuronal inhibition
primary BZDs used for sedation in ICU
lorazepam, midazolam
adverse effects of BZDs
respiratory depression, CV effects, withdrawal, delayed emergence from sedation, potential delirium association
when can BZD withdrawal occur, what happens during withdrawal, and how to prevent it
with abrupt discontinuation, risk of seizures, gradual tapering is required
what increases a patient's risk of having delayed emergence from sedation with BZDs
prolonged infusion, advanced age, hepatic/renal insufficiency
specific BZD that is affected by hepatic/ renal insufficiency
midazolam
preferred route of administration for lorazepam
IV preferred
onset/ duration of action of lorazepam and why
least lipid soluble, delayed onset and prolonged duration of effect
why is lorazepam not expected to accumulate in the elderly
metabolized into inactive metabolite by glucuronidation
consequences of propylene glycol (PG) solvent in IV formulations of lorazepam
potential lactic acidosis, nephrotoxicity after high doses or prolonged infusions
what to monitor if concerned about PG concentrations with lorazepam, what value may indicate potential toxicity
osmol gap, >10
why is lorazepam not the best choice if rapid awakening is required
intermediate half life
onset of midazolam and why
increased lipid solubility, rapid onset
how is midazolam metabolized and what increases the half life
hepatically metabolized by CYP4503A, t1/2 increased in elderly, hepatic disease, numerous drug interactions
what causes prolonged/ unpredictable effects of midazolam and why
prolonged use- can lead to metabolite accumulation
what type of use is midazolam recommended for
short term use (<48 hours) for shorter awakening times
alkylphenol sedative and hypnotic agent with rapid onset and rapid offset
propofol
why is propofol growing popularity for procedural sedation
very titratable
metabolism and Vd of propofol
hepatically metabolized, highly protein bound with large Vd
what patient population is propofol used in and why
neurosurgical patients, reduces ICP and rapid resolution of sedative effects following d/c
why do you need to account for propofol in nutritional assessments
it is an emulsion in a phospholipid vehicle that provides 1.1 kcal/mL
result of long term infusion of propofol and monitoring
hypertriglyceridemia, check TGs following 48h of treatment and periodically thereafter
max hang length for propofol
12 hours
most important adverse effect of propofol and common features
propofol infusion syndrome (acidosis, bradycardia, lipidemia)
risk factors of propofol infusion syndrome
sustained treatment (>48 hours), high doses (>75 ug/kg/min)
monitoring to watch out for propofol infusion syndrome
TGs, CK, LFTs, metabolic acidosis, bradycardia, hypotension
preservatives in propofol that may cause ADRs
EDTA, sodium metabisulfate, benzyl alcohol and benzyl alcohol/sodium benzoate
what can occur from EDTA in Diprivan
electrolyte abnormalities after >7 days of treatment
what patients have a greater risk of allergic reactions to sodium metabisulfate in propofol
allergic reactions
how to avoid withdrawal from propofol
gradual tapering of dose esp if >7 days of therapy
when is propofol the preferred sedative and what is it widely used for
when rapid awakening is important and in neurotrauma, widely use in procedural sedation
selective a2 agonist that inhibits excitatory neurotransmitters
dexmedetomidine
what is different about sedation from dexmedetomidine compared to other agents
patients readily arousable with gentle stimulation, analgesic sparing effects, no respiratory depression
when to not use dexmedetomidine
when deep sedation is required
t1/2 and metabolism of dexmedetomidine
short half life, hepatically metabolized
how is dexmedetomidine dose changed in hepatic dysfunction
decrease dose by 40-70%
what dosing is recommended by the dexmedetomidine PI that is not actually followed and why
loading infusion over 10-20 minutes, it increases CV effects
how to administer dexmedetomidine loading infusion to avoid CV effects
administer over longer time (>30 minutes) or with lower loading dose
main adverse effects seen with dexmedetomidine and what patients are most likely to experience this
bradycardia and hypotension, more seen in volume depleted patients or patients with increased sympathetic tone
what patients should dexmedetomidine not be used in
hemodynamic instability/ high sympathetic tone
when is dexmedetomidine use recommended over propfol
in mechanically ventilated ICU patients where light sedation and/or delirium reduction are priortized
cardinal features of delirium
decreased clarity of awareness of environment with a reduced ability to focus AND either a change in cognition or development of a perpetual disturbance
2 subtypes of delirium and which is often misdiagnosed
hyperactive (agitated)
hypoactive (calm/lethargic)- often misdiagnosed
what occurs with longer duration of delirium
greater chance for prolonged and irreversible impairment, associated with increased length of ICU stay and potentially mortality
modifiable risks for delirium
BZDs and blood transfusions + prolonged physical restraint or immobility
assessment tools to assess delirium
ICDSC or CAM-ICU
nonpharm delirium treatment
reduce environmental causes, early mobilization, optimization of sleep, optimization of hearing and vision
when is pharmacological treatment not recommended for delirium
prevention
may be used short term for treatment of delirium associated with significant stress
antipsychotics (haloperidol or atypical antipsychotics)
recommended for delirium where agitation is precluding weaning of vent/ extubation and why
dexmedetomidine because it does not cause respiratory depression
antipsychotic with mild sedation without analgesia or amnesia
haloperidol
main adverse effect of haloperidol
prolongation of QT interval on ECG, potential TdP
when to d/c haloperidol due to TdP risk
if Qtc exceeds 450 msec or increases >25% from baseline
other adverse effects of haloperidol
decreases seizure threshold, possible EPS, neuroleptic malignant syndrome (NMS)
what are the atypical antipsychotics and why are they potentially preferred over haloperidol
risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone
less adverse effects (QTc prolongation/EPS)
which atypical antipsychotic has the highest rate of prolonged QTc interval
ziprasidone
which atypical antipsychotic is associated with NMS
olanzapine
sedation guidelines
less is more, sedation should only be used if required, goal is calm but arousable patient
measures that encourage light sedation
daily interruption of sedative infusions with retitration
nursing-protocolized targeted sedation
what is recommended to be trialed first when it comes to sedation and why
analgesia first sedation recommended, pain is often primary source of agitation
which sedative agents are least preferred
BZDs
preferred sedative when rapid awakening is desired or in neurotrauma
propofol